TY - JOUR
T1 - Mechanisms and Barriers in Cancer Nanomedicine
T2 - Addressing Challenges, Looking for Solutions
AU - Anchordoquy, Thomas J.
AU - Barenholz, Yechezkel
AU - Boraschi, Diana
AU - Chorny, Michael
AU - Decuzzi, Paolo
AU - Dobrovolskaia, Marina A.
AU - Farhangrazi, Z. Shadi
AU - Farrell, Dorothy
AU - Gabizon, Alberto
AU - Ghandehari, Hamidreza
AU - Godin, Biana
AU - La-Beck, Ninh M.
AU - Ljubimova, Julia
AU - Moghimi, S. Moein
AU - Pagliaro, Len
AU - Park, Ji Ho
AU - Peer, Dan
AU - Ruoslahti, Erkki
AU - Serkova, Natalie J.
AU - Simberg, Dmitri
N1 - Publisher Copyright:
© 2017 American Chemical Society.
PY - 2017/1/24
Y1 - 2017/1/24
N2 - Remarkable progress has recently been made in the synthesis and characterization of engineered nanoparticles for imaging and treatment of cancers, resulting in several promising candidates in clinical trials. Despite these advances, clinical applications of nanoparticle-based therapeutic/imaging agents remain limited by biological, immunological, and translational barriers. In order to overcome the existing status quo in drug delivery, there is a need for open and frank discussion in the nanomedicine community on what is needed to make qualitative leaps toward translation. In this Nano Focus, we present the main discussion topics and conclusions from a recent workshop: "Mechanisms and Barriers in Nanomedicine". The focus of this informal meeting was on biological, toxicological, immunological, and translational aspects of nanomedicine and approaches to move the field forward productively. We believe that these topics reflect the most important issues in cancer nanomedicine.
AB - Remarkable progress has recently been made in the synthesis and characterization of engineered nanoparticles for imaging and treatment of cancers, resulting in several promising candidates in clinical trials. Despite these advances, clinical applications of nanoparticle-based therapeutic/imaging agents remain limited by biological, immunological, and translational barriers. In order to overcome the existing status quo in drug delivery, there is a need for open and frank discussion in the nanomedicine community on what is needed to make qualitative leaps toward translation. In this Nano Focus, we present the main discussion topics and conclusions from a recent workshop: "Mechanisms and Barriers in Nanomedicine". The focus of this informal meeting was on biological, toxicological, immunological, and translational aspects of nanomedicine and approaches to move the field forward productively. We believe that these topics reflect the most important issues in cancer nanomedicine.
UR - http://www.scopus.com/inward/record.url?scp=85018193113&partnerID=8YFLogxK
U2 - 10.1021/acsnano.6b08244
DO - 10.1021/acsnano.6b08244
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 28068099
AN - SCOPUS:85018193113
SN - 1936-0851
VL - 11
SP - 12
EP - 18
JO - ACS Nano
JF - ACS Nano
IS - 1
ER -